1. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial
- Author
-
Mulligan, K, Glidden, DV, Anderson, PL, Liu, A, McMahan, V, Gonzales, P, Ramirez-Cardich, ME, Namwongprom, S, Chodacki, P, De Mendonca, LMC, Wang, F, Lama, JR, Chariyalertsak, S, Guanira, JV, Buchbinder, S, Bekker, LG, Schechter, M, Veloso, VG, Grant, RM, Vargas, L, Sanchez, J, Mai, C, Saokhieo, P, Murphy, K, Gilmore, H, Holland, S, Faber, E, Duda, J, Bewerunge, L, Batist, E, Hoskin, C, Brown, B, De Janeiro, R, Beppu-Yoshida, C, Da Costa, MD, Assis De Jesus, SC, Grangeiro Da Silva, JR, Millan, R, De Siqueira Hoagland, BR, Martinez Fernandes, N, Da Silva Freitas, L, Grinsztejn, B, Pilotto, J, Bushman, L, Zheng, JH, Anthony Guida, L, Kline, B, Goicochea, P, Manzo, J, Hance, R, McConnell, J, Defechereux, P, Levy, V, Robles, M, Postle, B, Burns, D, and Rooney, J
- Subjects
Adult ,Male ,musculoskeletal diseases ,Microbiology (medical) ,Cytoplasm ,medicine.medical_specialty ,Adolescent ,Bone density ,Anti-HIV Agents ,Urology ,Placebo-controlled study ,Administration, Oral ,HIV Infections ,Emtricitabine ,Placebo ,Chemoprevention ,Placebos ,Plasma ,Young Adult ,Pre-exposure prophylaxis ,Absorptiometry, Photon ,Double-Blind Method ,immune system diseases ,Bone Density ,Internal medicine ,Humans ,Medicine ,Tenofovir ,Articles and Commentaries ,business.industry ,virus diseases ,Middle Aged ,Emtricitabine/Tenofovir ,Confidence interval ,Discontinuation ,Infectious Diseases ,Endocrinology ,Female ,business ,medicine.drug - Abstract
Author(s): Mulligan, Kathleen; Glidden, David V; Anderson, Peter L; Liu, Albert; McMahan, Vanessa; Gonzales, Pedro; Ramirez-Cardich, Maria Esther; Namwongprom, Sirianong; Chodacki, Piotr; de Mendonca, Laura Maria Carvalo; Wang, Furong; Lama, Javier R; Chariyalertsak, Suwat; Guanira, Juan Vicente; Buchbinder, Susan; Bekker, Linda-Gail; Schechter, Mauro; Veloso, Valdilea G; Grant, Robert M; Preexposure Prophylaxis Initiative Study Team | Abstract: BackgroundDaily preexposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency virus (HIV) acquisition. Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people. We report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in transgender women.MethodsDual-energy X-ray absorptiometry was performed at baseline and 24-week intervals in a substudy of iPrEx, a randomized, double-blind, placebo-controlled trial of FTC/TDF PrEP. Plasma and intracellular tenofovir concentrations were measured in participants randomized to FTC/TDF.ResultsIn 498 participants (247 FTC/TDF, 251 placebo), BMD in those randomized to FTC/TDF decreased modestly but statistically significantly by 24 weeks in the spine (net difference, -0.91% [95% confidence interval {CI}, -1.44% to -.38%]; P = .001) and hip (-0.61% [95% CI, -.96% to -.27%], P = .001). Changes within each subsequent 24-week interval were not statistically significant. Changes in BMD by week 24 correlated inversely with intracellular tenofovir diphosphate (TFV-DP), which was detected in 53% of those randomized to FTC/TDF. Net BMD loss by week 24 in participants with TFV-DP levels indicative of consistent dosing averaged -1.42% ± 29% and -0.85% ± 19% in the spine and hip, respectively (P l .001 vs placebo). Spine BMD tended to rebound following discontinuation of FTC/TDF. There were no differences in fractures (P = .62) or incidence of low BMD.ConclusionsIn HIV-uninfected persons, FTC/TDF PrEP was associated with small but statistically significant decreases in BMD by week 24 that inversely correlated with TFV-DP, with more stable BMD thereafter.Clinical trials registrationNCT00458393.
- Published
- 2015
- Full Text
- View/download PDF